Results 91 to 100 of about 1,141 (182)

Multidrug resistance mechanisms and therapeutic strategies in Candida auris [PDF]

In recent years, Candida auris has emerged as a formidable global health threat due to its multidrug resistance, high transmissibility in healthcare settings, and diagnostic challenges. Unlike most Candida species, C. auris can colonize the skin, persist
Alkaabi, Sara
core   +2 more sources

The Significance of Mono‐ and Dual‐Effective Agents in the Development of New Antifungal Strategies

Chemical Biology &Drug Design, Volume 105, Issue 1, January 2025.
The future of treating challenging fungal infections lies in novel therapies targeting new antifungal targets, overcoming resistance mechanisms, and exploring innovative dual inhibitors. ABSTRACT Invasive fungal infections (IFIs) pose significant challenges in clinical settings, particularly due to their high morbidity and mortality rates.
Cengiz Zobi, Oztekin Algul
wiley   +1 more source

The Candida auris Infection After the COVID‐19 Pandemic Seems to be an Urgent Public Health Emergency: A Call to Attention

Health Science Reports, Volume 7, Issue 11, November 2024.
Abstract Background and Aims Inconsequential diseases can sometimes become extremely dangerous through mutation. Antifungal resistance has increased by 24%, and resistance only due to Candida auris (C. auris) species have increased by 60%. Here, we aimed to assess the knowledge of antifungal treatment and preventative measures to mitigate the ...
Md. Ashrafur Rahman, Evangelos Victoros, Yeasna Shanjana, Marie Roke Thomas, Md. Rabiul Islam   +4 more
wiley   +1 more source

Phase I study of the pharmacokinetics and safety of rezafungin in subjects with moderate/severe hepatic impairment and matched control subjects

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, Volume 44, Issue 6, Page 435-443, June 2024.
Abstract Introduction Rezafungin is a second‐generation, once‐weekly echinocandin antifungal approved for the treatment of invasive candidiasis, including candidemia. In phase II/III studies of rezafungin versus caspofungin, patients with severe hepatic impairment were excluded due to lack of caspofungin data in this population. This open‐label, single‐
Shawn Flanagan, Voon Ong, Thomas Marbury, Alena Jandourek, Ronak G. Gandhi, Taylor Sandison   +5 more
wiley   +1 more source

Successful treatment with rezafungin after micafungin for relapsing Rasamsonia argillacea species complex pneumonia in a patient with bronchiectasis: A case report

International Journal of Infectious Diseases
Rasamsonia argillacea species complex are emerging opportunistic molds increasingly reported in patients with chronic lung disease. We describe a 69-year-old woman with bronchiectasis who developed relapsing R. aegroticola pneumonia.
Hugo Bes-Berlandier, Noémie Coron, Heloise Pottier, Sabrina Manni, Coline Mortier, Jean Philippe Bouchara, Coralie Barrera, Anne-Pauline Bellanger-Clerget, Laurence Millon, Perrine Parize, Fanny Lanternier, Olivier Lortholary, Julien Bermudez, Nadim Cassir, Benjamin Coiffard   +14 more
doaj   +1 more source

Exploring the Depths of Cryptic Aspergillosis: Species Variability, Clinical Spectrum, Diagnostic Quandaries and Therapeutic Options [PDF]

Journal of Clinical and Diagnostic Research
Cryptic aspergillosis, characterised by infections caused by non classical Aspergillus species, presents unique challenges in clinical management due to species variability, diverse clinical manifestations, diagnostic complexities, and limited treatment ...
Almas Fathima Upaisal, Anupma Jyoti Kindo   +1 more
doaj   +1 more source

Novel drugs approved by the EMA, the FDA, and the MHRA in 2023: A year in review

British Journal of Pharmacology, Volume 181, Issue 11, Page 1553-1575, June 2024.
Abstract In 2023, seventy novel drugs received market authorization for the first time in either Europe (by the EMA and the MHRA) or in the United States (by the FDA). Confirming a steady recent trend, more than half of these drugs target rare diseases or intractable forms of cancer.
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam Cortese‐Krott, Dave A. Kendall, Kirill A. Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Mauro M. Teixeira, Nathalie Vergnolle, Xin Wang, Péter Ferdinandy   +16 more
wiley   +1 more source

A Mini-Review of In Vitro Data for Candida Species, Including C. auris, Isolated during Clinical Trials of Three New Antifungals: Fosmanogepix, Ibrexafungerp, and Rezafungin

Journal of Fungi
This mini-review summarizes the clinical outcomes and antifungal susceptibility results, where available, for three new antifungals, including fosmanogepix, ibrexafungerp, and rezafungin, against Candida isolates cultured from patients in clinical trials.
Ana Espinel-Ingroff, Nathan P. Wiederhold   +1 more
doaj   +1 more source

What is the role of microbial biotechnology and genetic engineering in medicine?

MicrobiologyOpen, Volume 13, Issue 2, April 2024.
Microbial biotechnology, the technological application of microorganisms, has been instrumental in producing significant natural bioactive products. These include antibiotics, antifungals, anticancer drugs, antiparasitics, antivirals, immunosuppressants, toxoid vaccines, and therapeutic enzymes.
Fernando Santos‐Beneit
wiley   +1 more source

Fungal lung disease. [PDF]

Fungal lung disease encompasses a wide spectrum of organisms and associated clinical conditions, presenting a significant global health challenge. The type and severity of disease are determined by underlying host immunity and infecting fungal strain ...
Agarwal, Ritesh, Chotirmall, Sanjay, Delhaes, Laurence, Hage, Chadi, Jaggi, Tavleen, Langelier, Charles, Lydon, Emily, Shah, Anand, Tiew, Pei, Waterer, Grant   +9 more
core   +1 more source